Levetiracetam Tablet
Product Images NDC 80425-0565

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 80425-0565). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam 500mg #120 (Levetiracetam 500mg Tablet 80425 0565 01)

Levetiracetam 500 mg tablet bottle label from Advanced Rx of Tennessee, LLC. The label indicates 120 tablets, with storage instructions between 20° and 25°C (68° and 77°F). It includes NDC 80425-0565, comparison to Keppra, barcode, lot number, and expiration date 12/31/2030.*

FDA Label Image

Levetiracetam 500mg #30 (Levetiracetam 500mg Tablet 80425 0565 02)

Levetiracetam 500 mg tablet label from Advanced Rx of Tennessee, LLC. The label includes product name, strength, quantity (#30), NDC 80425-0565-02, lot number placeholder, expiration date 12/31/2030, source NDC 27808-0264-01, and manufacturer TRIS Pharma Inc. Storage instructions and a barcode are also visible.*

FDA Label Image

Levetiracetam 500mg #60 (Levetiracetam 500mg Tablet 80425 0565 03)

Levetiracetam 500 mg oral tablet packaging label showing quantity of 60 tablets. Label includes NDC 80425-0565-03, expiration date 12/31/2030, lot number placeholder XXXXXXX, and manufacturer Advanced Rx of Tennessee, LLC in Nashville, TN. Storage instructions recommend 20° to 25°C. The label references the comparator brand Keppra and source NDC 27808-0264-01 by Tris Pharma Inc.*

FDA Label Image

Levetiracetam 500mg #90 (Levetiracetam 500mg Tablet 80425 0565 04)

Levetiracetam 500 mg oral tablet package label from Advanced Rx of Tennessee, LLC, with quantity #90. The label includes NDC 80425-0565-04 and references source NDC 27808-0264-01 from Tris Pharma Inc. It notes storage conditions between 20° and 25°C and features barcode and lot/expiration placeholders.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of Levetiracetam. The diagram shows the molecular structure with labeled atoms and bonds characteristic of Levetiracetam.*

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows the percentage of patients from 0% to 45%, with bars indicating approximately 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day. Each bar has asterisks above it indicating statistical significance.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

Bar chart depicting the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The vertical axis shows patient percentage, and each bar indicates higher patient response with increasing Levetiracetam dosage.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

Bar graph comparing percentages of patients between placebo group and Levetiracetam 3000 mg/day group. The y-axis shows percentage of patients, with placebo at 14.4% (N=104) and Levetiracetam at 39.4% (N=180). A statistical significance marker is present above the Levetiracetam bar.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The graph shows 19.6% for the Placebo group and 44.6% for the Levetiracetam group, with an asterisk indicating statistical significance for the Levetiracetam group.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar graph comparing the percentage of patients between two groups: Placebo (N=51) at 19.6% and Levetiracetam (N=58) at 43.1%. The vertical axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar chart comparing the percentage of patients for two groups: Placebo (N=84) and Levetiracetam (N=79). The Levetiracetam group shows a higher percentage of patients (72.2%) compared to the Placebo group (45.2%). Percentages are displayed on the vertical axis from 0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.